Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance (PERSEUS)
The PERSEUS Registry - Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance
PERSEUS is an academic, investigator-initiated, multicenter observational registry of adults with acute pulmonary embolism (PE), promoted by Azienda Ospedaliero-Universitaria Careggi (Florence, Italy). It collects data generated during routine care across the whole course of the disease: pre-hospital care when available, emergency department presentation, the hospital stay (including bedside reassessments in the first 48 hours when performed as part of care) and follow-up up to 5 years. The registry has a retrospective cohort (patients diagnosed from 1 January 2023 until local ethics committee approval, with data taken from medical records) and a prospective cohort (consecutive patients enrolled after approval). Taking part in the registry does not change patient care: all tests and treatments are decided by the treating physicians. The registry aims to describe how acute PE is managed in everyday practice and how often patients die (from any cause and from PE), deteriorate hemodynamically, have recurrent venous thromboembolism or bleeding, and develop long-term complications such as chronic thromboembolic pulmonary hypertension. The database also supports ancillary analyses with separate pre-specified analysis plans, such as the evaluation of existing risk-stratification tools.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
BACKGROUND AND SCIENTIFIC RATIONALE
Pulmonary embolism (PE) represents a major cause of emergency department (ED) presentation, critical care admission, and early mortality. Despite advances in diagnostic algorithms and therapeutic strategies, intermediate- and high-risk PE patients remain challenging to risk-stratify dynamically during the acute phase. Current prognostic tools often rely solely on baseline single-point parameters, neglecting acute pathophysiological changes during the initial 48 hours of treatment. The PERSEUS Registry is designed to bridge this gap by capturing comprehensive, granular real-world data spanning the acute presentation, dynamic in-hospital course, and long-term surveillance.
STUDY DESIGN AND COHORTS
Time perspective: ambispective (retrospective and prospective cohorts, described below).
PERSEUS is an observational, ambispective, multicenter registry comprising two distinct phases:
- Retrospective Phase (Historical Cohort): Includes consecutive adult patients diagnosed with acute PE from January 1, 2023, up to the date of local Ethics Committee approval at each participating site. Data are abstracted from medical records.
- Prospective Phase (Contemporary Cohort): Enrolls consecutive adult patients presenting with acute PE after local Ethics Committee approval, extending for a continuous enrollment period of 5 years. Data are collected during routine care.
STUDY SETTING AND CLINICAL CONTINUUM OF CARE
Data collection spans the entire continuum of clinical care across participating academic, tertiary, and regional hospitals:
- Baseline Presentation (T0): Captures pre-hospital emergency medical service (EMS) data (initial vital signs, cardiac arrest, point-of-care ultrasound [POCUS], pre-hospital anticoagulation or thrombolysis), ED arrival parameters, clinical symptoms, arterial blood gas analysis, admission laboratory biomarkers (high-sensitivity troponin, BNP/NT-proBNP, lactate, D-dimer, renal function), electrocardiographic patterns, and multiorgan diagnostic imaging (CT pulmonary angiography [CTPA], complete echocardiography/POCUS, and compression venous ultrasound [CUS]).
- Dynamic In-Hospital Reassessment (T1-T4): To capture real-world hemodynamic and respiratory trajectories, serial parameters documented during standard clinical monitoring are recorded across predefined temporal windows: T1 (3-6 hours), T2 (6-12 hours), T3 (12-24 hours), and T4 (24-48 hours). Parameters include serial vital signs, shock index, respiratory support modalities, serial lactate/troponin kinetics, echocardiographic right ventricular function changes, and need for escalating hemodynamic or respiratory support (vasopressors, inotropes, non-invasive ventilation, mechanical ventilation, or ECMO).
- Hospital Discharge & Complications: Documents in-hospital adverse events, need for rescue reperfusion, procedural complications, bleeding events, length of stay, and vital status at discharge.
- Follow-up Surveillance: Thirty-day status is ascertained from clinical records. Follow-up then reflects routine care at 3 and 12 months and annually thereafter up to 5 years (in-person visit, telemedicine, telephone contact or review of clinical documentation), with regional mortality registries used to ascertain vital status when needed. Follow-up collects all-cause survival, cause of death, VTE recurrence, major and clinically relevant non-major bleeding, persistent functional limitation (modified Rankin Scale, exertional dyspnea, six-minute walk test when performed) and the development of chronic thromboembolic pulmonary hypertension (CTEPH).
OUTCOMES
Outcome definitions and time frames are reported in the Outcome Measures section.
DATA MANAGEMENT, QUALITY ASSURANCE, AND ETHICAL GOVERNANCE
Data collection is centralized using an electronic Case Report Form (eCRF) deployed on the REDCap (Research Electronic Data Capture) platform hosted on secure institutional servers at Azienda Ospedaliero-Universitaria Careggi (Florence, Italy).
- Privacy and Data Segregation: Strict GDPR compliance is maintained. Patient data are pseudonymized at source by the local site investigator using site-specific Subject IDs. The decoding key linking the alphanumeric ID to personal identifiers is maintained exclusively at the local participating hospital under the responsibility of the local Principal Investigator.
- Data Access Groups (DAGs): REDCap DAGs are enforced to compartmentalize site-level access, ensuring participating centers can exclusively view, enter, and edit their own center's records, with no unauthorized cross-center data visibility.
- Quality Assurance: The eCRF includes built-in validation rules (range and logic checks). The coordinating center performs regular central monitoring for inconsistencies, outliers and missing data, and discrepancies are resolved with each center through a formal query process. The Steering Committee reviews enrollment, data quality and protocol adherence every 6 months.
- Regulatory Framework: Protocol version 2.0 (7 May 2026) received a favourable opinion from the Comitato Etico Regione Toscana - Area Vasta Centro (CEAVC, register no. 30742_oss, meeting of 9 June 2026) for the sites of Azienda Ospedaliero-Universitaria Careggi and Azienda USL Toscana Centro. Participation of other national and international centers is subject to approval of a protocol amendment and of the competent local ethics committees. The study is conducted in accordance with the Declaration of Helsinki, Good Clinical Practice principles and applicable privacy regulations (including Article 110-bis of the Italian Privacy Code).
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Simone Vanni, MD, PhD
- 전화번호: +393666904459
- 이메일: simone.vanni@unifi.it
연구 연락처 백업
- 이름: Matteo Gabriele Monda, MD
- 전화번호: +393209433394
- 이메일: matteogabriele.monda@gmail.com
연구 장소
-
-
-
Madrid, 스페인
- 모병
- Hospital Universitario Ramón y Cajal
-
연락하다:
- David Jiménez, MD, PhD
- 전화번호: +34913368000
- 이메일: djimenez.hrc@gmail.com
-
수석 연구원:
- David Jiménez, MD, PhD
-
-
-
-
-
Lido di Camaiore, 이탈리아
- 모병
- Ospedale Versilia - Azienda USL Toscana Nord Ovest
-
연락하다:
- Gisueppe Pepe, MD
- 전화번호: +3905846051
- 이메일: giuseppe.pepe@uslnordovest.toscana.it
-
수석 연구원:
- Giuseppe Pepe, MD
-
Naples, 이탈리아, 80131
- 모병
- AORN Antonio Cardarelli
-
연락하다:
- Angela Iannuzzi, MD
- 전화번호: +390817471111
- 이메일: angela.iannuzzi@aocardarelli.it
-
수석 연구원:
- Angela Iannuzzi, MD
-
Perugia, 이탈리아, 06129
- 모병
- Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia
-
연락하다:
- Cecilia Becattini, MD, PhD
- 전화번호: +390755781
- 이메일: cecilia.becattini@unipg.it
-
수석 연구원:
- Cecilia Becattini, MD, PhD
-
Pisa, 이탈리아
- 모병
- Azienda Ospedaliero-Universitaria Pisana - Ospedale Cisanello
-
연락하다:
- Lorenzo Ghiadoni, MD, PhD
- 전화번호: +39050992111
- 이메일: lorenzo.ghiadoni@unipi.it
-
수석 연구원:
- Lorenzo Ghiadoni, MD, PhD
-
Torino, 이탈리아, 10126
- 모병
- AOU Città della Salute e della Scienza di Torino - Presidio Molinette
-
연락하다:
- Fulvio Morello, MD
- 전화번호: +390116335555
- 이메일: fulvio.morello@unito.it
-
수석 연구원:
- Fulvio Morello, MD
-
-
Tuscany
-
Bagno a Ripoli, Tuscany, 이탈리아, 50012
- 모병
- Ospedale Santa Maria Annunziata - Azienda USL Toscana Centro
-
연락하다:
- Germana Ruggiano, MD
- 전화번호: +39 055 69361
- 이메일: germana.ruggiano@uslcentro.toscana.it
-
Borgo San Lorenzo, Tuscany, 이탈리아, 50032
- 모병
- Nuovo Ospedale del Mugello - Azienda USL Toscana Centro
-
연락하다:
- Leonardo Delli, MD
- 전화번호: +39 055 84511
- 이메일: leonardo.delli@uslcentro.toscana.it
-
Empoli, Tuscany, 이탈리아, 50053
- 모병
- Ospedale San Giuseppe - Azienda USL Toscana Centro
-
연락하다:
- Paola Bartalucci, MD
- 전화번호: +39 0571 7051
- 이메일: paola.bartalucci@uslcentro.toscana.it
-
Florence, Tuscany, 이탈리아, 50134
- 모병
- Azienda Ospedaliero-Universitaria Careggi
-
연락하다:
- Simone Vanni, MD, PhD
- 전화번호: +393666904459
- 이메일: simone.vanni@unifi.it
-
연락하다:
- Matteo Gabriele Monda, MD
- 전화번호: +393209433394
- 이메일: matteogabriele.monda@gmail.com
-
수석 연구원:
- Simone Vanni, MD, PhD
-
부수사관:
- Matteo Gabriele Monda, MD
-
Florence, Tuscany, 이탈리아, 50122
- 모병
- Ospedale Santa Maria Nuova - Azienda USL Toscana Centro
-
연락하다:
- Michele Lanigra, MD
- 전화번호: +39 055 69381
- 이메일: michele.lanigra@uslcentro.toscana.it
-
Florence, Tuscany, 이탈리아, 50143
- 모병
- Ospedale San Giovanni di Dio (Torregalli) - Azienda USL Toscana Centro
-
연락하다:
- Gianfranco Giannasi, MD
- 전화번호: +39 055 69321
- 이메일: gianfranco.giannasi@uslcentro.toscana.it
-
Pescia, Tuscany, 이탈리아, 51017
- 모병
- Ospedale Santi Cosma e Damiano - Azienda USL Toscana Centro
-
연락하다:
- Gianluca Buffini, MD
- 전화번호: +39 0572 4601
- 이메일: gianluca.buffini@uslcentro.toscana.it
-
Pistoia, Tuscany, 이탈리아, 51100
- 모병
- Ospedale San Jacopo - Azienda USL Toscana Centro
-
연락하다:
- Mirco Donati, MD
- 전화번호: +39 0573 3521
- 이메일: mirco.donati@uslcentro.toscana.it
-
Prato, Tuscany, 이탈리아, 59100
- 모병
- Ospedale Santo Stefano - Azienda USL Toscana Centro
-
연락하다:
- Matteo Gabriele Monda, MD
- 전화번호: +393209433394
- 이메일: matteogabriele.monda@gmail.com
-
연락하다:
-
수석 연구원:
- Simone Magazzini, MD
-
-
-
-
-
Warsaw, 폴란드
- 모병
- Medical University of Warsaw - Infant Jesus Teaching Hospital
-
연락하다:
- Piotr Pruszczyk, MD, PhD
- 전화번호: +48225021000
- 이메일: piotr.pruszczyk@wum.edu.pl
-
수석 연구원:
- Piotr Pruszczyk, MD, PhD
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Consecutive adults with objectively confirmed acute pulmonary embolism diagnosed at participating hospitals, from emergency department presentation through hospitalization, including patients presenting with obstructive shock or cardiac arrest.
설명
Inclusion Criteria:
- Age 18 years or older at the time of presentation.
- Objectively confirmed diagnosis of acute pulmonary embolism (PE), with or without concomitant deep vein thrombosis (DVT) of the lower or upper extremities, confirmed by at least one of the following methods:
- Computed tomography pulmonary angiography (CTPA) demonstrating intraluminal filling defects in the pulmonary arterial tree;
- Ventilation/perfusion (V/Q) lung scintigraphy demonstrating high-probability mismatch;
- Conventional catheter-directed pulmonary angiography;
- In hemodynamically unstable patients (obstructive shock or cardiac arrest) in whom definitive imaging is not feasible: bedside point-of-care ultrasound showing clear signs of right ventricular overload together with proximal deep vein thrombosis, or mobile right heart thrombi.
- For the retrospective cohort: availability of medical records documenting clinical presentation and index diagnostic work-up at baseline (T0). The absence of serial reassessment timepoints (T1-T4) does not constitute an exclusion criterion.
- Written informed consent obtained from the patient or legal surrogate, or waiver/exception under Article 110-bis of the Italian Privacy Code (and applicable institutional ethical clearance) for deceased or untraceable patients.
Exclusion Criteria:
- Current active enrollment in an interventional experimental drug trial (blinded randomized clinical trial) where active drug allocation or protocol-mandated therapeutic regimen is unknown.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: OTHER
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Adults with acute pulmonary embolism
Consecutive adults with objectively confirmed acute pulmonary embolism, in two cohorts: a retrospective cohort (diagnoses from 1 January 2023 until local ethics committee approval; data abstracted from medical records) and a prospective cohort (consecutive enrollment after approval, for 5 years; data collected during routine care). |
Observational registry. Diagnostic and therapeutic management (laboratory tests, imaging, bedside ultrasound, anticoagulation, reperfusion and hemodynamic support) is entirely at the discretion of the treating physicians, according to routine institutional pathways and international guidelines. The registry only collects data generated in routine care.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
All-cause mortality at 30 days
기간: 30 days after diagnosis
|
Proportion of patients who die from any cause within 30 days of the objectively confirmed diagnosis of acute pulmonary embolism. Vital status is ascertained from hospital records, review of clinical documentation and, when needed, regional mortality registries. |
30 days after diagnosis
|
|
PE-related mortality at 30 days
기간: 30 days after diagnosis
|
Proportion of patients whose death within 30 days is adjudicated as a direct consequence of the index or a recurrent pulmonary embolism (PE). Fatal PE is defined as death occurring after objectively confirmed PE (index or recurrent event) in the absence of other identifiable causes, or confirmed at autopsy. For deaths occurring at home, information on the cause of death is actively sought. |
30 days after diagnosis
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Hemodynamic decompensation
기간: From diagnosis to hospital discharge or day 30, whichever comes first
|
Proportion of patients with new occurrence, after the initial assessment, of at least one of: persistent hypotension (systolic blood pressure <90 mmHg for 15 minutes or longer) or shock; need for continuous vasopressor or inotrope infusion; invasive mechanical ventilation; cardiac arrest; rescue reperfusion therapy (systemic, catheter-directed or surgical) for clinical deterioration. Reperfusion given as the initial treatment strategy is not counted as an event. |
From diagnosis to hospital discharge or day 30, whichever comes first
|
|
All-cause mortality during follow-up
기간: 3 months, 12 months, and annually up to 5 years after diagnosis
|
Proportion of patients who die from any cause during follow-up. |
3 months, 12 months, and annually up to 5 years after diagnosis
|
|
PE-related mortality during follow-up
기간: 3 months, 12 months, and annually up to 5 years after diagnosis
|
Proportion of patients whose death during follow-up is adjudicated as a direct consequence of the index or a recurrent pulmonary embolism, as defined for the 30-day PE-related mortality outcome. |
3 months, 12 months, and annually up to 5 years after diagnosis
|
|
Recurrent venous thromboembolism
기간: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
Proportion of patients with any new episode of pulmonary embolism or deep vein thrombosis (lower or upper limb, proximal or distal) confirmed by objective testing. Superficial vein thrombosis is not counted. |
30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
|
Major bleeding (ISTH criteria)
기간: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
Proportion of patients with major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH): overt bleeding that is fatal; or occurs in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome); or causes a fall in hemoglobin of 2 g/dL (1.24 mmol/L) or more, or leads to transfusion of two or more units of whole blood or red cells. Major bleeding is additionally classified as life-threatening if it is extracranial bleeding causing shock or intracranial hemorrhage with a Glasgow Coma Scale score below 14. |
30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
|
Clinically relevant non-major bleeding
기간: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
Proportion of patients with bleeding not meeting the criteria for major bleeding but requiring medical intervention, unscheduled contact with a physician, or temporary cessation of antithrombotic therapy. |
30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
|
Chronic thromboembolic pulmonary hypertension (CTEPH)
기간: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
Proportion of patients with CTEPH diagnosed during routine follow-up: mean pulmonary arterial pressure >20 mmHg, pulmonary arterial wedge pressure ≤15 mmHg and pulmonary vascular resistance >2 Wood units at right heart catheterization, with mismatched perfusion defects after at least 3 months of therapeutic anticoagulation (2022 ESC/ERS criteria). Diagnostic tests are performed only when clinically indicated. |
30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
|
Persistent functional limitation after pulmonary embolism (post-PE syndrome)
기간: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
Persistent or worsened exertional dyspnea compared with pre-event status, modified Rankin Scale score, and six-minute walk distance when performed in routine care. |
30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Simone Vanni, MD, PhD, Azienda Ospedaliero-Universitaria Careggi / University of Florence
- 연구 책임자: Matteo Gabriele Monda, MD, Azienda Ospedaliero-Universitaria Careggi / University of Florence
간행물 및 유용한 링크
일반 간행물
- Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):370-2. doi: 10.1161/ATVBAHA.108.162545. No abstract available.
- Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999 Apr 24;353(9162):1386-9. doi: 10.1016/s0140-6736(98)07534-5.
- Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jimenez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ni Ainle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. doi: 10.1093/eurheartj/ehz405. No abstract available.
- Jimenez D, de Miguel-Diez J, Guijarro R, Trujillo-Santos J, Otero R, Barba R, Muriel A, Meyer G, Yusen RD, Monreal M; RIETE Investigators. Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry. J Am Coll Cardiol. 2016 Jan 19;67(2):162-170. doi: 10.1016/j.jacc.2015.10.060.
- Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Radegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237. No abstract available.
- Barco S, Mahmoudpour SH, Valerio L, Klok FA, Munzel T, Middeldorp S, Ageno W, Cohen AT, Hunt BJ, Konstantinides SV. Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. Lancet Respir Med. 2020 Mar;8(3):277-287. doi: 10.1016/S2213-2600(19)30354-6. Epub 2019 Oct 12.
- Franco L, Becattini C, Beyer-Westendorf J, Vanni S, Nitti C, Re R, Manina G, Pomero F, Cappelli R, Conti A, Agnelli G. Definition of major bleeding: Prognostic classification. J Thromb Haemost. 2020 Nov;18(11):2852-2860. doi: 10.1111/jth.15048. Epub 2020 Sep 11.
- Vanni S, Pelagatti L, Caviglioli C, Fabiani G, Caldi F, Pellegrino A, Ottaviani M, Innocenti F, Nazerian P. TELOS-plus identifies normotensive patients with pulmonary embolism at high risk of 30-day mortality. Int J Cardiol. 2026 Feb 1;444:133974. doi: 10.1016/j.ijcard.2025.133974. Epub 2025 Oct 22.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
- 응급실
- 정맥혈전색전증
- 심초음파
- 위험 계층화
- 심정지
- 관찰 레지스트리
- 급성 폐색전증
- 폐 색전증
- 현장 진료 초음파
- 우심실 기능 장애
- 실제 증거
- ESC 가이드라인
- 병원 전 응급 치료
- 야심찬 코호트
- CT Pulmonary Angiography
- Prognostic Scores
- TELOS-plus
- sPESI
- Bova Score
- AHA/ACC Guidelines
- High-Sensitivity Troponin
- Plasma Lactate
- Hemodynamic Decompensation
- Systemic Thrombolysis
- Catheter-Directed Therapy
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- PERSEUS
- 30742_oss (기타 식별자: Ethics Committee Approval ID (Comitato Etico Regione Toscana - Area Vasta Centro, CEAVC))
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Pseudonymized individual participant data underlying published results may be shared with qualified researchers for methodologically sound proposals that fall within the scientific scope of the registry and do not overlap with analyses planned by the PERSEUS investigators. Sharing requires approval by the PERSEUS Steering Committee, approval by the competent ethics committee and a data transfer agreement with Azienda Ospedaliero-Universitaria Careggi, in compliance with the GDPR and the Italian Privacy Code.
IPD 공유 기간
Data will become available beginning 12 months after formal publication of the primary registry outcomes manuscript and will remain accessible for a period of 5 years.
IPD 공유 액세스 기준
Access requests must be submitted in writing to the Principal Investigator (simone.vanni@unifi.it) and the PERSEUS Steering Committee, including a detailed scientific protocol and statistical analysis plan. Proposals will be evaluated for scientific merit, feasibility, ethical compliance, and non-redundancy by the Steering Committee. Prior to data release, requestors and their home institutions must sign a formal Data Transfer Agreement (DTA) with Azienda Ospedaliero-Universitaria Careggi and obtain appropriate local ethical approval.
IPD 공유 지원 정보 유형
- 연구_프로토콜
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .